Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
Proceedings of the National Academy of Sciences of the United States of America|May 1, 2012
RNAs in Epstein-Barr virions control early steps of infectionSimon Jochum, Romana Ruiss, Andreas Moosmann, et al.Plos One|October 25, 2011
EBV-gp350 confers B-cell tropism to tailored exosomes and is a neo-antigen in normal and malignant B cells--a new option for the treatment of B-CLLRomana Ruiss, Simon Jochum, Ralph Mocikat, et al.Plos Pathogens|May 23, 2012
The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and eliminationSimon Jochum, Andreas Moosmann, Stephan Lang, et al.Frontiers in Immunology|December 19, 2022
Design and performance characteristics of the Elecsys anti-SARS-CoV-2 S assayKarin Taffertshofer, Mirko Walter, Peter Mackeben, et al.Journal of Virology|October 14, 2011
A virus-like particle-based Epstein-Barr virus vaccineRomana Ruiss, Simon Jochum, Gerhard Wanner, et al.Infectious Diseases and Therapy|December 26, 2024
SARS-CoV-2 SPIKE Antibody Levels can Indicate Immuno-Resilience to Re-infection: a Real-World StudyYue Jin, Fei Yang, Christopher M Rank, et al.Cancer Immunology, Immunotherapy : CII|February 5, 2011
Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCCChristina Battke, Romana Ruiss, Ulrich Welsch, et al.Frontiers in Immunology|February 7, 2022
Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 TrialSimon Jochum, Imke Kirste, Sayuri Hortsch, et al.Medrxiv : the Preprint Server for Health Sciences|October 13, 2021
Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trialSimon Jochum, Imke Kirste, Sayuri Hortsch, et al.Diagnostic Microbiology and Infectious Disease|July 25, 2021
Analytical performance evaluation of the Elecsys Epstein-Barr virus immunoassay panelUlrike Schulte-Spechtel, Mario Berth, Yi Lauseker-Hao, et al.Pageof 2